Rohto PharmaceuticalLtd Full Year 2025 Earnings: Revenues Disappoint

Rohto PharmaceuticalLtd (TSE:4527) Full Year 2025 Results

Key Financial Results

• Revenue: JP¥308.6b (up 14% from FY 2024).
• Net income: JP¥31.0b (flat on FY 2024).
• Profit margin: 10.0% (down from 11% in FY 2024). The decrease in margin was driven by higher expenses.
• EPS: JP¥136 (up from JP¥136 in FY 2024).

We check all companies for important risks. See what we found for Rohto PharmaceuticalLtd in our free report.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Rohto PharmaceuticalLtd Revenues Disappoint

Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Personal Products industry in Japan.

Performance of the Japanese Personal Products industry.

The company's shares are down 9.0% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Rohto PharmaceuticalLtd's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.